Skip to content
Clinical Trials – home

Neurosphera Sp. z o.o.

Verified siteinfo

Poland Ul. Taneczna 30, 02-829 Warsaw, Poland

  • 5 trials recruiting
  • Partial seizures · Lennox-Gastaut syndrome · Epilepsy
  • Adults and children

About Specializations

Neurosphera Sp. z o.o. in Warsaw, Poland specialises in clinical trials of conditions such as Partial seizures, Lennox-Gastaut syndrome, Epilepsy, Idiopathic generalised epilepsy, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology

The medical center is at the forefront of neurological research, with a particular focus on refractory focal onset epilepsy. This condition, characterized by seizures that are resistant to standard treatments, presents significant challenges in patient care.

  • Refractory Focal Onset Epilepsy
  • Seizure Reduction Strategies
  • Adjunctive Therapy Innovations

Through its research, the center is pioneering new therapeutic approaches, such as the development and testing of novel compounds like BHV-7000, aimed at significantly reducing seizure frequency and improving quality of life for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Taneczna 3002-829 WarsawPoland
Recruiting now
5 trials
Conditions studied
6
Partner status
Verified site

More sites in WarsawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

11 clinical trials

Study of SPN-817 (Huperzine A) in Adults with Focal Onset Seizures: Testing Safety and Effectiveness of Treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Huperzine A
  • Sponsor:Supernus Pharmaceuticals Inc.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Carisbamate
  • Sponsor:Sk Life Science Inc.

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Migraine

Not recruiting

Study of rimegepant for preventing chronic migraine in adolescents aged 12 to 17 years

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Rimegepant sulfate
  • Sponsor:Pfizer Inc.

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Partial seizures

Not recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Long-Term Safety of Soticlestat for Patients with Dravet or Lennox-Gastaut Syndromes

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Soticlestat
  • Sponsor:Takeda Development Center Americas Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.